300705 九典制药
已收盘 03-23 15:00:00
资讯
新帖
简况
九典制药（300705）披露获得富马酸依美斯汀缓释胶囊药品注册证书，3月20日股价下跌2.48%
证券之星 · 03-20 22:29
九典制药（300705）披露获得富马酸依美斯汀缓释胶囊药品注册证书，3月20日股价下跌2.48%
九典制药(300705.SZ)取得一项药品注册证书
智通财经网 · 03-20 17:16
九典制药(300705.SZ)取得一项药品注册证书
股市必读：九典制药（300705）3月13日披露最新机构调研信息
证券之星 · 03-16
股市必读：九典制药（300705）3月13日披露最新机构调研信息
九典制药：中泰证券投资者于3月12日调研我司
证券之星 · 03-13
九典制药：中泰证券投资者于3月12日调研我司
股市必读：九典制药（300705）3月4日董秘有最新回复
证券之星 · 03-05
股市必读：九典制药（300705）3月4日董秘有最新回复
九典制药（300705）披露国家集采接续采购中选结果，3月2日股价下跌3.04%
证券之星 · 03-02
九典制药（300705）披露国家集采接续采购中选结果，3月2日股价下跌3.04%
九典制药最新公告：获得阿仑膦酸钠口服溶液药品注册证书
证券之星 · 03-02
九典制药最新公告：获得阿仑膦酸钠口服溶液药品注册证书
九典制药：近半年内新获批上市的化药3类有阿仑膦酸钠口服溶液、马来酸曲美布汀片
证券之星 · 03-02
九典制药：近半年内新获批上市的化药3类有阿仑膦酸钠口服溶液、马来酸曲美布汀片
九典制药：完成回购1.24%公司股份，成交总金额1亿元
新京报 · 02-24
九典制药：完成回购1.24%公司股份，成交总金额1亿元
九典制药（300705）披露回购公司股份进展公告，2月3日股价上涨1.26%
证券之星 · 02-03
九典制药（300705）披露回购公司股份进展公告，2月3日股价上涨1.26%
九典制药为全资子公司九典宏阳提供3000万元担保
中金财经 · 02-02
九典制药为全资子公司九典宏阳提供3000万元担保
股市必读：九典制药（300705）1月26日董秘有最新回复
证券之星 · 01-27
股市必读：九典制药（300705）1月26日董秘有最新回复
九典制药完成工商变更登记 经营范围规范化调整
中金财经 · 01-15
九典制药完成工商变更登记 经营范围规范化调整
九典制药：中信建投、申万宏源等多家机构于1月13日调研我司
证券之星 · 01-14
九典制药：中信建投、申万宏源等多家机构于1月13日调研我司
九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%
证券之星 · 01-07
九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%
九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%
证券之星 · 01-05
九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%
九典制药2025年第四季度可转债转股26张，总股本微增至5亿股
中金财经 · 01-05
九典制药2025年第四季度可转债转股26张，总股本微增至5亿股
每周股票复盘：九典制药（300705）股东会通过章程修订等议案
证券之星 · 01-03
每周股票复盘：九典制药（300705）股东会通过章程修订等议案
九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%
证券之星 · 2025-12-31
九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%
九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%
证券之星 · 2025-12-26
九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%
加载更多
公司概况
公司名称：
湖南九典制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-10-10
主营业务：
湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品等的研发、生产、销售、CXO服务。公司的主要产品是药品制剂、原料药及药用辅料。公司先后获评安全生产标准化三级企业、安全生产示范企业等称号。
发行价格：
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":13.27,"timestamp":1774249380000,"preClose":14.15,"halted":0,"volume":9464724,"delay":0,"changeRate":-0.0622,"floatShares":369000000,"shares":500000000,"eps":0.9375,"marketStatus":"已收盘","change":-0.88,"latestTime":"03-23 15:00:00","open":14.02,"high":14.03,"low":13.21,"amount":128000000,"amplitude":0.058,"askPrice":13.28,"askSize":115,"bidPrice":13.27,"bidSize":115,"shortable":0,"etf":0,"ttmEps":0.9375,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":14.15,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":15.57,"lowLimit":12.74,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":500291126,"isCdr":false,"pbRate":2.69,"roa":"--","peRate":14.154667,"roe":"14.85%","epsLYR":1.05,"committee":0.393775,"marketValue":6639000000,"turnoverRate":0.0257,"status":1,"floatMarketCap":4895000000},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2620732152","title":"九典制药（300705）披露获得富马酸依美斯汀缓释胶囊药品注册证书，3月20日股价下跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732152","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620732152?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:29","pubTimestamp":1774016956,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，九典制药报收于14.15元，较前一交易日下跌2.48%，最新总市值为70.79亿元。九典制药于近日披露《关于获得药品注册证书的公告》。公告显示，公司于2026年3月20日收到国家药品监督管理局下发的《药品注册证书》，批准注册富马酸依美斯汀缓释胶囊，规格为2mg，剂型为胶囊剂。截至公告日，国内共有2家企业取得该药品注册证书，公司为国内第2家通过或视同通过仿制药质量和疗效一致性评价的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2620933781","title":"九典制药(300705.SZ)取得一项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620933781","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620933781?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:16","pubTimestamp":1773998197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九典制药(300705.SZ)公告，公司近日收到国家药品监督管理局下发的《药品注册证书》，药品名称为：富马酸依美斯汀缓释胶囊。富马酸依美斯汀缓释胶囊适用于治疗过敏性鼻炎和荨麻疹。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2619002291","title":"股市必读：九典制药（300705）3月13日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2619002291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619002291?lang=zh_cn&edition=full","pubTime":"2026-03-16 02:30","pubTimestamp":1773599431,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，九典制药报收于14.72元，上涨0.2%，换手率1.38%，成交量5.08万手，成交额7494.26万元。当日关注点来自交易信息汇总：3月13日主力资金净流出615.49万元，散户资金净流入437.63万元。公司有18个产品中选国家组织集采药品协议期满品种接续采购，有利于促进销售和市场拓展。JIJ02凝胶预计于2026年上半年完成I期临床试验，并启动II期临床。未来将结合市场环境与战略规划适时推出具体激励计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600000940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2619919811","title":"九典制药：中泰证券投资者于3月12日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619919811?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:30","pubTimestamp":1773401448,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月13日九典制药发布公告称中泰证券于2026年3月12日调研我司。九典制药2025年三季报显示，前三季度公司主营收入22.68亿元，同比上升5.69%；归母净利润4.06亿元，同比下降9.64%；扣非净利润3.91亿元，同比下降6.47%；其中2025年第三季度，公司单季度主营收入7.56亿元，同比下降3.03%；单季度归母净利润1.15亿元，同比下降30.59%；单季度扣非净利润1.08亿元，同比下降33.48%；负债率26.59%，投资收益-34.4万元，财务费用853.76万元，毛利率74.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300035214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600918","BK0276","300705","BK0239"],"gpt_icon":0},{"id":"2617557775","title":"股市必读：九典制药（300705）3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557775","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557775?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:17","pubTimestamp":1772644630,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，九典制药报收于14.53元，下跌2.09%，换手率1.67%，成交量6.17万手，成交额9042.76万元。董秘最新回复投资者： 截止2026年三月三号股东人是多少？公司股东人数按规定在定期报告中进行披露，请参见公司定期报告。当日关注点来自交易信息汇总：3月4日主力资金净流出1129.14万元，显示主力短期看空情绪明显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500000703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2616635560","title":"九典制药（300705）披露国家集采接续采购中选结果，3月2日股价下跌3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616635560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616635560?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:43","pubTimestamp":1772462597,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，九典制药报收于15.01元，较前一交易日下跌3.04%，最新总市值为75.09亿元。九典制药于近日披露《关于参与国家组织集采药品协议期满品种接续采购中选结果的公告》。中选结果自2026年3月起实施，至2028年12月31日结束。2024年度中选药品合计销售收入为43,140.46万元，占公司营业收入的14.72%；2025年前三季度为33,483.63万元，占比14.76%。本次中选有利于促进产品销售和市场拓展，提升品牌影响力。后续采购合同签订及市场执行情况存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2616838781","title":"九典制药最新公告：获得阿仑膦酸钠口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616838781","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616838781?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:23","pubTimestamp":1772443392,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称，公司近日收到国家药品监督管理局下发的《药品注册证书》，批准注册阿仑膦酸钠口服溶液。该药品适用于治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折（椎骨压缩性骨折），治疗男性骨质疏松症以增加骨量。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200024832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2616849593","title":"九典制药：近半年内新获批上市的化药3类有阿仑膦酸钠口服溶液、马来酸曲美布汀片","url":"https://stock-news.laohu8.com/highlight/detail?id=2616849593","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616849593?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:46","pubTimestamp":1772441190,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司近期有无新药上市？九典制药回复：尊敬的投资者：您好！公司近半年内新获批上市的化药3类有阿仑膦酸钠口服溶液、马来酸曲美布汀片，化药4类有硫酸氨基葡萄糖胶囊。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200023260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2613742799","title":"九典制药：完成回购1.24%公司股份，成交总金额1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613742799","media":"新京报","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613742799?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:22","pubTimestamp":1771924920,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 2月24日，九典制药发布公告称，截至公告日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购股份618.08万股，占公司目前总股本的1.24%，最高成交价为18.44元/股，最低成交价为14.51元/股，成交总金额为1亿元（不含交易费用）。至此，公司回购股份方案实施完毕。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/02/24/5690413226181861445.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/02/24/5690413226181861445.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1771924254129340.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1771924254129340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2608870384","title":"九典制药（300705）披露回购公司股份进展公告，2月3日股价上涨1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870384","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608870384?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:46","pubTimestamp":1770129981,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，九典制药报收于15.28元，较前一交易日上涨1.26%，最新总市值为76.44亿元。该股当日开盘15.17元，最高15.28元，最低15.08元，成交额达6365.25万元，换手率为1.14%。公司于2026年2月3日披露《关于回购公司股份的进展公告》。公告显示，湖南九典制药股份有限公司于2025年2月17日召开董事会，审议通过回购股份方案，拟通过集中竞价交易方式以自有资金和专项贷款回购股份，用于股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2608854779","title":"九典制药为全资子公司九典宏阳提供3000万元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854779","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854779?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:14","pubTimestamp":1770023684,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于近日发布公告，披露了其为全资子公司湖南九典宏阳制药有限公司提供担保的进展。九典制药已与兴业银行签订《最高额保证合同》，为九典宏阳提供最高本金余额为人民币3000万元的连带责任保证担保。该担保生效后，公司为九典宏阳提供的剩余担保总额度为人民币1.58亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260202/31992665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2606240262","title":"股市必读：九典制药（300705）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606240262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606240262?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:07","pubTimestamp":1769450832,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，九典制药报收于16.08元，上涨0.75%，换手率3.15%，成交量11.63万手，成交额1.86亿元。董秘最新回复投资者： 目前公司的股东人数是多少？公司股东人数按规定在定期报告中进行披露，请参见公司定期报告。感谢您对公司的关注！交易信息汇总资金流向1月26日主力资金净流出877.38万元；游资资金净流入1970.67万元；散户资金净流出1093.29万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2603072856","title":"九典制药完成工商变更登记 经营范围规范化调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2603072856","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603072856?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:43","pubTimestamp":1768480984,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于近日完成了工商变更登记手续，并取得了由长沙市市场监督管理局换发的新版《营业执照》。本次变更主要涉及公司经营范围的调整，系根据市场监督管理部门关于经营范围登记规范化的要求，通过规范表述查询系统选取匹配条目后进行的标准化更新。公司强调，此次调整仅为文字表述的规范化，未涉及公司实质经营内容的变动。此次工商变更源于公司2025年第二次临时股东会审议通过的《关于变更经营范围及修订的议案》，相关决议已于此前进行披露。同时，公司已依据核准后的经营范围完成了《公司章程》的修订及备案登记。本次变更标志着九典制药的公司治理及登记信息进一步符合监管规范。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260115/31945964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2603654195","title":"九典制药：中信建投、申万宏源等多家机构于1月13日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2603654195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603654195?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:08","pubTimestamp":1768352932,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月13日九典制药发布公告称中信建投、申万宏源、言是科技、彼得明奇于2026年1月13日调研我司。首先，在院内市场，公司将着力确保洛索洛芬钠凝胶贴膏在集采执行后的院内销量基础，同时重点推广酮洛芬凝胶贴膏及新收购的独家品种代温灸膏等品种。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400007032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300705","000166","BK0239","BK0012","BK1564","BK0276","BK0028","601066","BK1147","BK0183","06806"],"gpt_icon":0},{"id":"2601801273","title":"九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801273","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801273?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:42","pubTimestamp":1767796936,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，九典制药报收于15.51元，较前一交易日下跌0.19%，最新总市值为77.58亿元。公司近日发布公告，披露关于2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市的进展情况。公告显示，本次归属股票上市流通日为2026年1月9日，涉及人数1人，归属股票数量7.84万股，占公司总股本的0.016%。公司层面业绩考核达标，归属比例为100%。本次归属已完成股份登记，募集资金用于补充流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2601688735","title":"九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688735","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601688735?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:23","pubTimestamp":1767622998,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，九典制药报收于15.49元，较前一交易日上涨3.4%，最新总市值为77.48亿元。该股当日开盘15.06元，最高15.53元，最低15.0元，成交额达1.59亿元，换手率为2.82%。公司近日发布公告，就回购公司股份的进展情况作出说明。湖南九典制药股份有限公司于2025年2月17日召开董事会，审议通过回购股份方案，拟通过集中竞价交易方式以自有资金及专项贷款回购股份，用于股权激励。回购进展符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2601431002","title":"九典制药2025年第四季度可转债转股26张，总股本微增至5亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601431002","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601431002?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:25","pubTimestamp":1767605104,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于2026年1月5日披露了2025年第四季度可转换公司债券转股情况。公告显示，在2025年第四季度，公司发行的“九典转02”共有26张完成转股，对应债券票面金额2，600元，转换为公司股票172股，转股价格为14.95元/股。截至2025年12月31日，“九典转02”尚未转股部分剩余2，052，772张，剩余票面总金额约为2.05亿元。本次转股导致公司总股本发生微小变动，由500，212，488股增加至500，212，660股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31915320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2600067215","title":"每周股票复盘：九典制药（300705）股东会通过章程修订等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067215?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:00","pubTimestamp":1767380435,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：九典制药2025年第二次临时股东会审议通过变更经营范围及修订《公司章程》等议案。公司公告汇总湖南九典制药股份有限公司于2025年12月30日召开2025年第二次临时股东会，会议由董事会召集，采取现场与网络投票相结合方式举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2595720446","title":"九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720446?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:43","pubTimestamp":1767174180,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，九典制药报收于14.98元，较前一交易日下跌1.06%，最新总市值为74.93亿元。该股当日开盘15.14元，最高15.14元，最低14.98元，成交额达7093.21万元，换手率为1.28%。近日，九典制药发布2025年第二次临时股东会决议公告，公司于2025年12月30日召开2025年第二次临时股东会，审议通过《关于变更经营范围及修订<公司章程>的议案》和《关于制定及修订部分治理制度的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2594129411","title":"九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594129411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594129411?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:34","pubTimestamp":1766759657,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，九典制药报收于15.28元，较前一交易日下跌0.71%，最新总市值为76.43亿元。该股当日开盘15.39元，最高15.39元，最低15.24元，成交额达7043.14万元，换手率为1.24%。公司近日发布公告，将于2025年12月30日召开2025年第二次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为同日9:15至15:00。股权登记日为2025年12月19日。中小投资者表决结果将单独计票并披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774256474446,"stockEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":-0.08},{"period":"3month","weight":-0.0871},{"period":"6month","weight":-0.1807},{"period":"1year","weight":-0.18},{"period":"ytd","weight":-0.0554}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34736人(较上一季度减少10.37%)","perCapita":"10619股","listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","registeredCapital":"50029万元","survey":" 湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品等的研发、生产、销售、CXO服务。公司的主要产品是药品制剂、原料药及药用辅料。公司先后获评安全生产标准化三级企业、安全生产示范企业等称号。","listedPrice":10.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}